Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 1/2 6Phase 1 5Phase NA 1Phase EARLY_PHASE1 1Phase 4 1Phase 3 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 4Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Brain Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 6Temozolomide 3Biopsy 3Bevacizumab 3posaconazole 2fluciclovine F-18 2Topotecan 2Specimen Handling 2Radiosurgery 2Pemetrexed 2Nivolumab 2Methotrexate 2Ketoconazole 2Fluorodeoxyglucose F18 2ribociclib 1relatlimab 1mycophenolic adenine dinucleotide 1montelukast 1gancotamab 1fluoromisonidazole 1fluorodopa F 18 1fludarabine phosphate 1etoposide phosphate 1eribulin 1dexamethasone acetate 1dexamethasone 21-phosphate 1clevudine 1ceritinib 1brivaracetam 1auricularum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Brain Neoplasms × Trastuzumab × Clear all
NCT02735798 2017-05-04

64-Cu Labeled Brain PET/MRI for MM-302 in Advanced HER2+ Cancers With Brain Mets

University of California, San Francisco

Phase EARLY_PHASE1 Withdrawn
CNS

Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡